Placental PFAS Accumulation
The placenta serves as the interface between maternal and fetal circulation, and PFAS accumulate in placental tissue throughout pregnancy. Studies of placental samples collected at delivery have detected PFOS, PFOA, PFNA, and PFHxS at concentrations reflecting maternal serum PFAS levels. The placenta does not effectively exclude PFAS, allowing maternal exposure to translate directly into fetal exposure.
PFAS affect placental trophoblast cells — the specialized cells that form the placenta and facilitate nutrient and oxygen exchange. In vitro studies demonstrate that PFAS exposure impairs trophoblast invasion, viability, and hormone production.
Pregnancy Complications Associated With PFAS
Multiple epidemiological studies have found associations between higher maternal PFAS levels and increased risk of preeclampsia — a dangerous pregnancy complication characterized by high blood pressure and organ damage. PFAS may contribute to preeclampsia through disruption of angiogenic factors (VEGF and PlGF) that regulate placental blood vessel development.
Intrauterine growth restriction (IUGR) and low birth weight are also associated with prenatal PFAS exposure. A meta-analysis of prospective cohort studies found that each doubling of maternal PFOA level was associated with approximately 19 grams lower birth weight — a small but significant effect with implications for infant health outcomes.
Protective Measures During Pregnancy
Obstetricians and midwives practicing in PFAS-contaminated regions should include water quality discussion in prenatal care. Switching to reverse osmosis filtered water before and during pregnancy reduces maternal and fetal PFAS exposure during the critical developmental window.
Women with prior pregnancy complications — particularly preeclampsia or growth restriction — may have had unrecognized PFAS exposure as a contributing factor, and future pregnancy planning should include environmental exposure assessment and mitigation.